• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Biotechnology’s Role in Improving Stroke Outcomes

    CEO Spotlight: Marc Kikuchi

    Newsmakers: Darren Shirley

    Are You Prepared for the 2023 DSCSA Deadline?

    Rethinking the Changing Role of the CRO
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    AskBio Appoints Clinical Ops Executives

    SpectrumX Partners With UK Contract Manufacturer

    GL Chemtec Partners with Edgewater Capital to Accelerate Growth

    Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership

    Almac Invests $65M to Expand North American HQ
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    SpectrumX Partners With UK Contract Manufacturer

    Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership

    Almac Invests $65M to Expand North American HQ

    Captor Therapeutics Selects CDMO for Clinical Trial Materials

    Catalent to Acquire Metrics Contract Services for $475M
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    UPS to Acquire Healthcare Logistics Provider Bomi Group

    Marken to Acquire Medical Courier Business of Cedra Express

    5 Key Features of Agile Pharmaceutical Packaging Supply Chains That Drive Results

    Novavax Expands Manufacturing Agreement with SK bioscience

    Lonza Continues to Lead the Market with Innovative Hard Empty Capsules
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    GL Chemtec Partners with Edgewater Capital to Accelerate Growth

    West Pharmaceutical Makes Strategic Investment in Latch Medical

    “3 Key Trends” with James Park

    Captor Therapeutics Selects CDMO for Clinical Trial Materials

    Behind Every Successful eCOA Solution is a Robust Scientific Strategy
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Chime Biologics Receives Commercial Manufacturing License

    Automation Is Key to Meeting Demands in Pharmacovigilance

    UBC Acquires Examoto

    Responding to Consumer Complaints While Working with CMOs

    WuXi Vaccines Receives GMP Certificate from HPRA
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    IDT Biologika

    Aphena Pharma Solutions

    Kyongbo Pharmaceutical

    Qosina

    CMC Pharmaceuticals
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    IDT Biologika

    Aphena Pharma Solutions

    Kyongbo Pharmaceutical

    Qosina

    CMC Pharmaceuticals
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Online Exclusives

    Driving Efficiencies in Today’s Complex Trials

    Murray Aitken of IQVIA discusses CRO market trends, post-pandemic opportunities, and leveraging tech-enabled services and capabilities.

    Driving Efficiencies in Today’s Complex Trials
    Related CONTENT
    • Bora Pharmaceuticals
    • Legacy Pharma Solutions
    • SGS Health Science
    • PCI Pharma Services
    • pHOXBIO Unveils Trial Results from COVID Prophylactic Nasal Spray
    Kristin Brooks, Managing Editor, Contract Pharma06.03.21
    Clinical trials have been transformed over the last year as a result of the pandemic, with many traditional processes taking on new formats to increase clinical development efficiencies. Technology and digital modernization of clinical trials, as well as advanced therapies and personalized medicine, and the transition to decentralized clinical trials resulting from the pandemic, are key areas driving clinical trials today. Additionally, the increasing number of drugs in various phases of development, along with growing R&D expenditure, are driving outsourcing in the clinical trial space.

    Murray Aitken, Executive Director, IQVIA Institute for Human Data Science discusses key market trends, post-pandemic opportunities, and driving efficiencies in today’s complex trials.

    Contract Pharma: What are the key market trends driving opportunities and outsourcing?

    Murray Aitken: COVID-19 really pushed the industry to take a closer look at the changing landscape and how we can continue clinical development with more efficiency without compromising data quality or safety. Several key drivers of change, include:
     
    Patient-centric decentralized clinical trial design: We used to bring the patient to the trial. Now, the idea is to design trials that fit into patients’ lives seamlessly and reduces burdens placed on them and sites to improve patient engagement. We are seeing a dramatic ramp-up in decentralized trial elements whether it be telehealth technologies and virtual oversight models to assist sites and engage with patients or home health visits to perform lab work, infusions and other home care needs. And, patients are simply more engaged and savvy about managing their own healthcare. The use of social media and technology-enabled referrals is increasing patient awareness, access, recruitment, and participation at a time when it’s needed most.

    ·       Remote trial execution: As digitization is occurring at a rapid pace, so does the use of remote capabilities throughout the entirety of a trial from start-up to clinical monitoring and data review. It is important that CROs and sponsors avoid increased burden on sites and patients when designing such models.
     
    Additionally, it is critical to recognize that disparities seen in COVID-19 research highlighted the industry’s increasing focus on ensuring underrepresented communities, including communities of color, are sufficiently represented in clinical trials. Through education and awareness, these communities can have access to treatment options that currently are not available to them. It is vital for CROs to help sponsors modulate trial enrollment and prioritize engagement among disproportionately affected populations in clinical development.
     
    CP: What are the current market challenges?

    MA: In response to the pandemic last year, sponsors, sites, CROs and regulatory agencies made decisions and rapidly shifted gears to re-start or keep trials on track. Then, in going through the ebbs and flows of the pandemic, the industry adjusted strategies to ensure trials catch-up to, meet, or exceed intended goals for drug development. Now, in some cases, there will still be catching up in trial programs and adjustments in term of how everyone works. The challenge is to continue maintaining data integrity within trials, while protecting the safety of patients, HCPs, and colleagues.
     
    We have also yet to see how the so-called backlog of patients – people who missed routine check-ups, screenings and diagnosis visits during 2020 – will be cleared this year and beyond. In particular, we think about how many patients will present with more advanced disease than usual, and how that will impact the flow of patients into clinical trials. Typical patient journeys, which should always include clinical research as a care option, are being re-mapped as a consequence of the pandemic.
     
    Health delivery systems, including investigator sites, are also facing immediate challenges due to the disruption to their business models caused by the pandemic.  How they manage through these challenges now, more than a year of disruption, will also have an impact on clinical trial activity for the remainder of this year and beyond.
     
    CP: What do you anticipate for clinical development post pandemic?

    MA: The pandemic has helped push for a united urgency in the industry to accelerate trial design and execution and related timelines and ensure burdens placed on patients and sites are reduced as we look to bring therapies to market quicker and with more quality for patients in need. It has also highlighted what can be done when stakeholders collaborate in pursuit of a common goal, when technologies are fully embraced, and when flexibility, speed and agility are top priorities.  Learning from the pandemic, we see a shift in what is expected from the industry moving forward:
     
    ·       Greater acceptance of patient-centric trial elements. Seeing how research was sustained through pandemic-related shutdowns and site closures via decentralized trial solutions, sponsors will consider how virtual they can go with their trials to best meet the needs within their therapeutic areas of focus.

    ·       Need for transparency and collaboration. In the fight against COVID-19, siloed information such as study protocols were available to all, creating a level of transparency for study teams, sponsors and most importantly, patients that we have never seen before. Also, we experienced collaborations between private sector pharmaceutical companies and governmental agencies to meet public health needs around the pandemic. It is something that can trickle into other therapeutic areas as well.

    ·       Focus on underrepresented communities in research. Disparities among COVID-19 research heightened the industry’s increasing understanding of the true need to ensure underrepresented communities are sufficiently represented in clinical trials. Though the industry is moving at a rapid pace, we are seeing sponsors deliberately slow enrollment in trials to better ensure representation of diverse communities.
     
    Beyond the pandemic’s effects, we also see the surge of innovative science, particularly in oncology, rare diseases, and neuroscience, driving significant increases in the number of candidate drugs for clinical development. For example, in our IQVIA Institute report on R&D trends, we show that oncology clinical trial starts in 2020 were up 60% over the level in 2015. We have also seen a record inflow of venture capital funding for life sciences companies up 50% in 2020 compared to 2019, and increased funding of R&D by large pharma companies. These are very positive trends for advancing healthcare and patients that do require new approaches to trial design and execution that can accommodate this swelling of the clinical development pipeline – by sponsors, sites, regulators and CROs. 
     
    CP: What capabilities are needed for today’s complex clinical trials?

    MA: CROs have to be agile, adaptable and scalable in services and capabilities to help sponsors effectively navigate through the complex clinical development landscape.
     
    Tech-enabled services and capabilities such as artificial intelligence (AI), machine learning, decentralized trials, telehealth, direct-to-patient models and remote monitoring not only kept trials moving during the pandemic, but in some cases, accelerated timelines while maintaining data quality and patient safety. While integration and use of these elements increases, it is equally important for CROs to provide related expertise to ensure the industry’s high quality data standard is maintained, if not elevated, while updating ecosystems in trial design and execution. All the while, CROs also have to ensure burdens on patients and their loved ones and study teams are reduced in the process.
     
    CP: What’s critical to driving efficiency?

    MA: Disruptive technologies such as AI are helping to resolving challenges inherent to the clinical trial process. Embracing intelligent, intuitive technologies, sponsors and CROs are able to better orchestrate outcomes that help get much-needed treatments to patients faster with heightened productivity and efficiency. The seamless integration of systems and data and interoperability is replacing disparate point solutions.
     
    Sponsors and service providers are working to evaluate the implications of these opportunities, both in terms of the technologies themselves, but more importantly, how to integrate and normalize the data from these sources such that valuable insights are fully visible and can be obtained to support more streamlined decision making and effective process improvement.
     
    Additionally, process automation through AI is helping to eliminate repetitive tasks and reduce administrative burden to free staff for higher-level responsibilities, including spending more time with patients. This type of productivity could impact every phase of the clinical trial process.


    Murray Aitken is the executive director of the IQVIA Institute for Human Data Science. Mr. Aitken is a renowned expert on the challenges facing the global healthcare industry, and the prospects for improving patient outcomes through managing costs and maximizing access through Human Data Science. Throughout his 15-year tenure at IQVIA, Mr. Aitken has served in various roles responsible for healthcare insights, corporate strategy, and consulting. Prior to his time at IQVIA, Mr. Aitken was a partner at McKinsey & Company in New Jersey and Los Angeles in the U.S. and in Seoul, South Korea, covering a broad range of industries, including life sciences and consumer goods.
    Related Searches
    • Drug Development
    • Clinical Trials
    • Information Technology
    Suggested For You
    Bora Pharmaceuticals Bora Pharmaceuticals
    Legacy Pharma Solutions Legacy Pharma Solutions
    SGS Health Science SGS Health Science
    PCI Pharma Services PCI Pharma Services
    pHOXBIO Unveils Trial Results from COVID Prophylactic Nasal Spray pHOXBIO Unveils Trial Results from COVID Prophylactic Nasal Spray
    Immunic Inc. Signs In-License Agreement with University Medical Center Goettingen, Germany Immunic Inc. Signs In-License Agreement with University Medical Center Goettingen, Germany
    Naobios to Manufacture FluGen’s M2SR Flu Vax Candidate  Naobios to Manufacture FluGen’s M2SR Flu Vax Candidate
    Clean Cells Expands Bioproduction Capabilities Clean Cells Expands Bioproduction Capabilities
    CEO Spotlight: Gaston Salinas, Botanical Solution Inc. CEO Spotlight: Gaston Salinas, Botanical Solution Inc.
    Lakes BioScience Signs Agreement with Cytvia Lakes BioScience Signs Agreement with Cytvia
    Boyds Opens US Office in PA Boyds Opens US Office in PA
    GeneQuine, Exothera Enter Gene Therapy Partnership GeneQuine, Exothera Enter Gene Therapy Partnership
    Boehringer Ingelheim, Twist Bioscience Enter Antibody Discovery Collaboration Boehringer Ingelheim, Twist Bioscience Enter Antibody Discovery Collaboration
    Repligen and Navigo Launch Antibody Technology Platform Repligen and Navigo Launch Antibody Technology Platform
    GeneQuine Contracts Exothera to Support the Development of Its Osteoarthritis Gene Therapy GeneQuine Contracts Exothera to Support the Development of Its Osteoarthritis Gene Therapy

    Related Buyers Guide Companies

    • Bora Pharmaceuticals

      Bora Pharmaceuticals

      ...
      Lonnie Barish, VP, Business Development 03.09.22

    • Legacy Pharma Solutions

      Legacy Pharma Solutions

      ...
      Nathan Bender, Director, Sales & Marketing 12.07.21

    • Chemistry | Extractables and Leachables | Microbiology
      SGS Health Science

      SGS Health Science

      ...
      Jessica Martin, Marketing Director 10.26.21


    • Drug Development
      PCI Pharma Services

      PCI Pharma Services

      ...
      Jessica Kloster, Marketing Manager 10.20.21

    • Breaking News | Clinical Trials
      pHOXBIO Unveils Trial Results from COVID Prophylactic Nasal Spray

      pHOXBIO Unveils Trial Results from COVID Prophylactic Nasal Spray

      According to the study, the novel prophylactic nasal spray prevented infection from SARS-CoV-2, the virus that causes COVID-19.
      09.22.21

    Loading, Please Wait..
    Trending
    • Almac Invests $65M To Expand North American HQ
    • Just – Evotec Biologics And Alpine Immune Sciences Expand Partnership
    • West Pharmaceutical Makes Strategic Investment In Latch Medical
    • AskBio Appoints Clinical Ops Executives
    • Catalent To Acquire Metrics Contract Services For $475M
    Breaking News
    • AskBio Appoints Clinical Ops Executives
    • GL Chemtec Partners with Edgewater Capital to Accelerate Growth
    • SpectrumX Partners With UK Contract Manufacturer
    • Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership
    • Almac Invests $65M to Expand North American HQ
    View Breaking News >
    CURRENT ISSUE

    July/August 2022

    • Biotechnology’s Role in Improving Stroke Outcomes
    • CEO Spotlight: Marc Kikuchi
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Charlotte’s Web Sports Product Line to Undergo NSF Certification Process
    ADM and Benson Hill Partner to Scale High Protein Soy for U.S. Market
    Tazo Transitions to Regenerative Organic Agriculture
    Coatings World

    Latest Breaking News From Coatings World

    What are you Reading this Week?
    SONGWON Industrial Group Reports Strong Q2 Financial Results
    PPG Completes COLORFUL COMMUNITIES Project for Boys & Girls Clubs of Greater Houston
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    MPO's Most-Read Stories This Week—Aug. 13
    'Graft-on-a-Chip' Built to Improve Vascular Graft Success
    Abbott Invests €440 in New Irish Facility
    Contract Pharma

    Latest Breaking News From Contract Pharma

    AskBio Appoints Clinical Ops Executives
    SpectrumX Partners With UK Contract Manufacturer
    GL Chemtec Partners with Edgewater Capital to Accelerate Growth
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Arkay Chairman Emeritus Howard Kaneff Has Died
    Nutricosmetics Market to Hit $13.7 Billion by 2030
    Estée Lauder Pledges 100% Electric Fleet of Vehicles by 2030
    Happi

    Latest Breaking News From Happi

    Consumers are Clamoring for Vintage Glam: Spate
    Kayali’s Lovefest Fragrance, Newell’s New Candle and HydraFacial’s Record Financial Results
    Self Care Trumps Home Care Post-Covid
    Ink World

    Latest Breaking News From Ink World

    Weekly Recap: Printing Ink Primer, Zeller+Gmelin Lead This Week’s News Stories
    Heidelberg Enjoys Successful Start to 2022-23 Fiscal Year
    Mimaki Announces New LATAM Website
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Esko, Constantia Flexibles announce acquisitions and more
    Hybrid Software joins The Flexo Xperience Center
    Flexo Wash LLC and Mike Potter celebrate 20 years
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Weekly Recap: Essity Switches to Recyclable Packs for Feminine Pads, FTC Sues PPE Maker on False Origin Claims & More
    Focke & Co. to Host Destination: Your Hygiene Hub on August 31
    Exports Dominate Chinese Trade of Tissues, Hygiene Products and Wipes
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    ODT's Most-Read Stories This Week—Aug. 13
    Dental 3D Printing Market is Expanding 20% Annually
    Study Results Released for Abbott's Concussion Blood Test
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Weekly Recap: ALTANA, Universal Display and Emerson Top This Week’s Stories
    eMagin Corporation Announces 2Q 2022 Results
    Zebra Technologies’ Emission Reduction Targets Validated by SBTi

    Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login